FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNoxopharm Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
NOX.AX
Noxopharm Limited Stock AnalysisComprehensive stock analysis for Noxopharm Limited (NOX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNOX.AX
NOX.AX
Noxopharm Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
NOX.AX
  1. Home
  2. Stocks
  3. Noxopharm Limited

Noxopharm Limited

🇦🇺NOX.AX•ASX

Noxopharm Limited

🇦🇺NOX.AX•ASX

Your view on NOX.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Noxopharm Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Olivier Laczka
Headquarters
60 Linksley Avenue, Glenhaven, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Olivier Laczka
Headquarters
60 Linksley Avenue, Glenhaven, NSW, AU
Description

Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers.

Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer.

The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries.

Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma.

Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Noxopharm Limited. Starting points for Noxopharm Limited: EPS -AUD 0.02, beta 0.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Noxopharm Limited. Noxopharm Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Noxopharm Limited. Trailing twelve-month EPS for Noxopharm Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Noxopharm Limited. Noxopharm Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NOX.AX20 companies
Compare NOX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
BDX.AXBCAL Diagnostics LimitedHealthcareMedical - Diagnostics & Research—
HMD.AXHeraMED LimitedHealthcareMedical - Devices—
IDT.AXIDT Australia LimitedHealthcareDrug Manufacturers - Specialty & Generic—
IMC.AXImmuron LimitedHealthcareBiotechnology—
NC6.AXNanollose LimitedHealthcareBiotechnology—
OSL.AXOncoSil Medical LtdHealthcareMedical - Devices—
PAB.AXPatrys LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ONCYOncolytics Biotech Inc.HealthcareNASDAQ$44.2M
ONPHOncology Pharma Inc.HealthcareOTC$109,553
ONTTFOxford Nanopore Technologies plcHealthcareOTC$1.8B
OPORFhVIVO plcHealthcareOTC$59.2M
ORGSOrgenesis Inc.HealthcareOTC$3.0M
ORICORIC Pharmaceuticals, Inc.HealthcareNASDAQ$795.1M
ORKAOruka Therapeutics, Inc.HealthcareNASDAQ$6.5B
ORMPOramed Pharmaceuticals Inc.HealthcareNASDAQ$169.2M
ORPOFOSE Immunotherapeutics S.A.HealthcareOTC$260.3M
ORYZFOryzon Genomics S.A.HealthcareOTC$283.9M
OSRHWOSR Holdings, Inc.HealthcareNASDAQ$7.8M
OSTXOS Therapies IncorporatedHealthcareAMEX$48.1M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Noxopharm Limited.

NOX.AX AnalysisWeak
Past
1
Growth
1
Health
1
Profit
1
Value
1